Stock SPEC SPECTRACURE AB
Add to a list
To use this feature you must be a member
Log inSign up

News SpectraCure AB

Equities

SPEC

SE0007158118

Market Closed - Nasdaq Stockholm
Other stock markets
 16:29:38 10/05/2024 BST 		5-day change 1st Jan Change
2.99 SEK 0.00% Intraday chart for SpectraCure AB -6.56% -22.54%
02-23 Spectracure AB Continues in the Process of Initiating A Clinical Study, for Primary Localised Prostate Cancer CI
02-22 SpectraCure AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
SpectraCure takes the next step in the work with the new clinical study
AQ
Spectracure AB Continues in the Process of Initiating A Clinical Study, for Primary Localised Prostate Cancer
CI
SpectraCure AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
A well-accomplished annual audit in accordance with ISO 13485:2016
AQ
Expert group comments on results of ongoing study
AQ
SpectraCure AB Conducts a Clinical Study for Patients with Recurrence of Prostate Cancer After Radiotherapy
CI
SpectraCure : Masoud Khayyami presents SpectraCure at investor meetingon November 5 in Lund!
PU
SpectraCure AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
SpectraCure has decided to seek approval for a clinical study of primary prostate cancer
AQ
SpectraCure AB Decides to Seek Approval for Clinical Study of Primary Prostate Cancer
CI
SpectraCure : Meet SpectraCure’s board member, Homer Pien!
PU
SpectraCure strengthens presence among urologists
AQ
SpectraCure AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
SpectraCure has been awarded an additional EU grant for industrialisation of the company's treatment system Q-PRO®
AQ
SpectraCure Receives an Additional EU Grant
CI
SpectraCure AB Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
SpectraCure AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
CI
SpectraCures signs Letter of Intent with Cheplapharm
AQ
SpectraCures Signs Letter of Intent with Cheplapharm
CI
SpectraCure : First treatment with Q-PRO and integrated image management technology
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SPEC Stock
  4. News SpectraCure AB